Literature DB >> 29176750

Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Maaike Cockx1, Mieke Gouwy1, Jo Van Damme2, Sofie Struyf1.   

Abstract

Patients with primary ciliary dyskinesia (PCD) and cystic fibrosis (CF), two inherited disorders, suffer from recurrent airway infections characterized by persistent bacterial colonization and uncontrollable inflammation. Although present in high counts, neutrophils fail to clear infection in the airways. High levels of C-X-C motif chemokine ligand 8/interleukin-8 (CXCL8/IL-8), the most potent chemokine to attract neutrophils to sites of infection, are detected in the sputum of both patient groups and might cause the high neutrophil influx in the airways. Furthermore, in CF, airway neutrophils are highly activated because of the genetic defect and the high levels of proinflammatory chemoattractants and cytokines (e.g., CXCL8/IL-8, tumor necrosis factor-α and IL-17). The overactive state of neutrophils leads to lung damage and fuels the vicious circle of infection, excessive inflammation and tissue damage. The inflammatory process in CF airways is well characterized, whereas the lung pathology in PCD is far less studied. The knowledge of CF lung pathology could be useful to guide molecular investigations of the inflammatory processes in PCD lungs. Current available therapies can not completely remedy the chronic airway infections in these diseases. This review gives an overview of the role that chemoattractants and cytokines play in these neutrophil-dominated lung pathologies. Finally, the most frequently applied treatments in CF and PCD and new experimental therapies to reduce neutrophil-dominated airway inflammation are described.

Entities:  

Keywords:  chemoattractants; cystic fibrosis; cytokines; primary ciliary dyskinesia

Mesh:

Substances:

Year:  2017        PMID: 29176750      PMCID: PMC6052842          DOI: 10.1038/cmi.2017.118

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  127 in total

1.  Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects.

Authors:  Michael W Konstan; Jeanne E Krenicky; Marcie R Finney; H Lester Kirchner; Kathleen A Hilliard; Jay B Hilliard; Pamela B Davis; Charles L Hoppel
Journal:  J Pharmacol Exp Ther       Date:  2003-06-13       Impact factor: 4.030

2.  Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.

Authors:  R H Lawrence; T C Sorrelli
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 3.  Treatment recommendations in Primary Ciliary Dyskinesia.

Authors:  Deepika Polineni; Stephanie D Davis; Sharon D Dell
Journal:  Paediatr Respir Rev       Date:  2015-10-20       Impact factor: 2.726

4.  Management of primary ciliary dyskinesia in European children: recommendations and clinical practice.

Authors:  Marie-Pierre F Strippoli; Thomas Frischer; Angelo Barbato; Deborah Snijders; Elisabeth Maurer; Jane S A Lucas; Ernst Eber; Bulent Karadag; Petr Pohunek; Zorica Zivkovic; Amparo Escribano; Chris O'Callaghan; Andrew Bush; Claudia E Kuehni
Journal:  Eur Respir J       Date:  2012-01-26       Impact factor: 16.671

5.  Characterization of a chemotactic defect in patients with Kartagener syndrome.

Authors:  R J Walter; J R Danielson; H M Reyes
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-04

6.  Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis.

Authors:  J M Wolter; R L Rodwell; S D Bowler; J G McCormack
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

Review 7.  How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis.

Authors:  Sarah McCuaig; James G Martin
Journal:  Lancet Respir Med       Date:  2013-01-30       Impact factor: 30.700

8.  Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1.

Authors:  J Van Damme; M De Ley; G Opdenakker; A Billiau; P De Somer; J Van Beeumen
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

9.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.

Authors:  Gerrit John; Ali O Yildirim; Bruce K Rubin; Dieter C Gruenert; Markus O Henke
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

Review 10.  Airway inflammation in cystic fibrosis.

Authors:  Arnon Elizur; Carolyn L Cannon; Thomas W Ferkol
Journal:  Chest       Date:  2008-02       Impact factor: 9.410

View more
  11 in total

1.  Chemokines: the past, the present and the future.

Authors:  Peng Tang; Ji Ming Wang
Journal:  Cell Mol Immunol       Date:  2018-03-26       Impact factor: 11.530

2.  Ccdc103 promotes myeloid cell proliferation and migration independent of motile cilia.

Authors:  Lauren G Falkenberg; Sarah A Beckman; Padmapriyadarshini Ravisankar; Tracy E Dohn; Joshua S Waxman
Journal:  Dis Model Mech       Date:  2021-05-24       Impact factor: 5.758

3.  ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure.

Authors:  Anja Schulz-Kuhnt; Vicky Greif; Kai Hildner; Lisa Knipfer; Michael Döbrönti; Sabine Zirlik; Florian Fuchs; Raja Atreya; Sebastian Zundler; Rocío López-Posadas; Clemens Neufert; Andreas Ramming; Alexander Kiefer; Anika Grüneboom; Erwin Strasser; Stefan Wirtz; Markus F Neurath; Imke Atreya
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

4.  Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat.

Authors:  Marcia Rodrigues da Silva; Adriana Schapochnik; Mayara Peres Leal; Janete Esteves; Cristina Bichels Hebeda; Silvana Sandri; Christiane Pavani; Anna Carolina Ratto Tempestini Horliana; Sandra H P Farsky; Adriana Lino-Dos-Santos-Franco
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

Review 5.  Studying Neutrophil Function in vitro: Cell Models and Environmental Factors.

Authors:  Marfa Blanter; Mieke Gouwy; Sofie Struyf
Journal:  J Inflamm Res       Date:  2021-01-20

6.  DMBT1 is upregulated in cystic fibrosis, affects ciliary motility, and is reduced by acetylcysteine.

Authors:  Alexander Kiefer; Erika Plattner; Renate Ruppel; Christel Weiss; Zhe Zhou-Suckow; Marcus Mall; Marcus Renner; Hanna Müller
Journal:  Mol Cell Pediatr       Date:  2022-03-05

7.  The Antimicrobial Activity of Peripheral Blood Neutrophils Is Altered in Patients with Primary Ciliary Dyskinesia.

Authors:  Maaike Cockx; Marfa Blanter; Mieke Gouwy; Pieter Ruytinx; Sara Abouelasrar Salama; Sofie Knoops; Noëmie Pörtner; Lotte Vanbrabant; Natalie Lorent; Mieke Boon; Sofie Struyf
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

8.  Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis.

Authors:  Paolo Montuschi; Vincenzina Lucidi; Debora Paris; Enza Montemitro; Rugia Shohreh; Nadia Mores; Dominique Melck; Giuseppe Santini; Fabio Majo; Andrea Motta
Journal:  Front Pharmacol       Date:  2018-06-18       Impact factor: 5.810

9.  Aerosolized Bovine Lactoferrin Counteracts Infection, Inflammation and Iron Dysbalance in A Cystic Fibrosis Mouse Model of Pseudomonas aeruginosa Chronic Lung Infection.

Authors:  Antimo Cutone; Maria Stefania Lepanto; Luigi Rosa; Mellani Jinnett Scotti; Alice Rossi; Serena Ranucci; Ida De Fino; Alessandra Bragonzi; Piera Valenti; Giovanni Musci; Francesca Berlutti
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

Review 10.  Oxidative Stress and Endoplasmic Reticulum Stress in Rare Respiratory Diseases.

Authors:  María Magallón; Ana Esther Carrión; Lucía Bañuls; Daniel Pellicer; Silvia Castillo; Sergio Bondía; María Mercedes Navarro-García; Cruz González; Francisco Dasí
Journal:  J Clin Med       Date:  2021-03-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.